Every 10-Q that Aptevo Therapeutics Inc (APVO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow APVO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APVO filings page.
Aptevo Therapeutics Inc., a clinical-stage oncology biotech, reported a net loss of $13.1 million for the six months ended June 30, 2026 and an accumulated deficit of $288.3 million. Cash and cash equivalents were $9.8 million, with net cash used in operating activities of $13.4 million over the same period, driving a decline in stockholders’ equity to $6.0 million from $17.4 million at year-end 2025.
The company states that recurring losses, negative operating cash flows, and limited cash resources raise substantial doubt about its ability to continue as a going concern for one year from issuance of the financial statements. Management discloses that existing cash is not expected to fund operations for at least that period and that additional capital will be required to advance its pipeline.
Aptevo continues development of lead candidate mipletamig in frontline AML and ALG.APV-527 in solid tumors, alongside multiple preclinical ADAPTIR and ADAPTIR-FLEX assets. Recent non-dilutive and strategic funding steps include a $1.5 million CARE Fund grant commitment for APVO451 and a 50/50 radiopharmaceutical collaboration with Niowave, accompanied by a $0.5 million equity investment. Equity financings in 2025–2026, including Standby Equity Purchase Agreements and warrant transactions, have provided cash but also created a large warrant overhang and, under August 2026 agreements, restrict further use of the SEPAs and ATM facility for 12 months after shareholder approval.
Aptevo Therapeutics reported another quarterly loss and raised doubt about its ability to continue as a going concern. For the three months ended March 31, 2026, the company recorded a net loss of $6.7 million, driven by research and development expenses of $3.9 million and general and administrative costs of $2.9 million.
Cash and cash equivalents fell to $14.5 million from $21.6 million at year-end, with $8.0 million used in operating activities in the quarter. Management states that recurring losses, negative operating cash flow, and limited cash resources create substantial doubt about Aptevo’s ability to continue as a going concern over the next year, and the company expects to rely on equity facilities and other financings to fund its oncology pipeline.
Aptevo Therapeutics (APVO) filed its Q3 2025 10‑Q, reporting a quarterly net loss of $7.5 million and a nine‑month net loss of $20.2 million. Operating expenses rose as R&D reached $4.0 million and G&A was $3.6 million for the quarter. A warrant down‑round adjustment recorded a $1.5 million deemed dividend, increasing loss attributable to common stockholders.
Cash and cash equivalents were $21.1 million at September 30, 2025, up from $8.7 million year‑end, driven by $32.7 million year‑to‑date financing cash inflows. The company raised $18.7 million, net in Q3 via its SEPA with Yorkville and ATM program, plus $4.1 million net after quarter‑end. Stockholders’ equity improved to $17.4 million. Year‑to‑date operating cash use was $20.4 million.
Financing capacity includes $10.0 million remaining under the SEPA; the ATM currently has no availability under Form S‑3 I.B.6 limits. Common warrants outstanding totaled 12,535,033, all exercisable. The company effected a 1‑for‑20 reverse split in May 2025. Clinical updates highlight mipletamig AML combination data with high remission rates and no CRS among evaluable frontline patients. Shares outstanding were 16,850,494 as of November 6, 2025.
Aptevo Therapeutics (APVO) reported a net loss of $12.6 million for the six months ended June 30, 2025 and a three-month loss of $6.2 million, driven by research and development and general and administrative expenses. Cash and cash equivalents were $9.41 million at June 30, 2025, and net cash used in operating activities for the six months was $13.7 million, resulting in an accumulated deficit of $260.2 million.
The company disclosed that substantial doubt exists about its ability to continue as a going concern for the one-year period from issuance. Since quarter-end Aptevo completed multiple equity financings that raised $15.9 million and entered a $25.0 million standby equity purchase agreement, and established an ATM program (originally $50.0 million, prospectus later updated to $8.0 million available under Form S-3 limits). The company also has 12,585,033 common warrants outstanding that could generate additional proceeds if exercised.